|
US2020323884A1
|
|
Treatment of migraine
|
|
CA2894686A1
|
|
Use of pregn-4-en-20-yn-3-one for the treatment of depressive disorders
|
|
BRPI0910637A2
|
|
Method for the treatment of a castrated male person suffering from shingles
|
|
AU2006287295A1
|
|
Acute treatment of social phobia
|
|
AU2003223572A8
|
|
Novel pheromone receptor
|
|
AU2002367386A1
|
|
Human pheromone receptors
|
|
WO02089814A1
|
|
17-METHYLENE-ANDROSTAN-3α-OL ANALOGS AS CRH INHIBITORS
|
|
WO0244381A2
|
|
Human vno receptor (r1)
|
|
AU3845601A
|
|
Human vno cdna libraries
|
|
US6544971B1
|
|
Method of increasing alertness by administration of a vomeropherin, and vomeropherin-emitting alarm devices
|
|
US6555531B1
|
|
Weight promoting composition, method, and product
|
|
BR9816142A
|
|
19-nor-colano steroids as neurochemical initiators of change in human hypothalamic function
|
|
US6331534B1
|
|
Steroids as neurochemical stimulators of the VNO to alleviate pain
|
|
US6117860A
|
|
Steroids as neurochemical stimulators of the VNO to treat paroxistic tachycardia
|
|
AU6380796A
|
|
Novel nor-pregnanes for inducing hypothalamic effects
|
|
NZ333837A
|
|
estrene steroids for inducing hypothalamic effects
|
|
MXPA94000705A
|
|
Estrene steroids as neurochemical initiators of change in human hypothalamic function and related pharmaceutical compositions.
|
|
EP0715517A1
|
|
Estrene steroids as neurochemical initiators of change in human hypothalamic function and related pharmaceutical compositions
|
|
NZ330570A
|
|
the use of estrene steroids as neurochemical initiators of change in human hypothalamic funtion
|
